263 related articles for article (PubMed ID: 31747618)
21. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
22. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
23. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
24. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
Zhang P; An K; Duan X; Xu H; Li F; Xu F
Drug Discov Today; 2018 Apr; 23(4):900-911. PubMed ID: 29373841
[TBL] [Abstract][Full Text] [Related]
26. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A
Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636
[TBL] [Abstract][Full Text] [Related]
27. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
28. Lipid-based Vehicles for siRNA Delivery in Biomedical Field.
Li T; Huang L; Yang M
Curr Pharm Biotechnol; 2020; 21(1):3-22. PubMed ID: 31549951
[TBL] [Abstract][Full Text] [Related]
29. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
30. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.
Biscans A; Coles A; Echeverria D; Khvorova A
J Control Release; 2019 May; 302():116-125. PubMed ID: 30940496
[TBL] [Abstract][Full Text] [Related]
31. The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery.
Ma XF; Sun J; Qiu C; Wu YF; Zheng Y; Yu MZ; Pei XW; Wei L; Niu YJ; Pang WH; Yang ZJ; Wang JC; Zhang Q
J Control Release; 2016 Aug; 235():99-111. PubMed ID: 27242198
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).
Mohseni M; Kucharski C; K C RB; Nasrullah M; Jiang X; Uludağ H; Brandwein J
PLoS One; 2021; 16(6):e0251719. PubMed ID: 34157051
[TBL] [Abstract][Full Text] [Related]
33. SiRNA delivery: challenges and role of carrier systems.
Shegokar R; Al Shaal L; Mishra PR
Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
[TBL] [Abstract][Full Text] [Related]
34. Attacking the genome: emerging siRNA nanocarriers from concept to clinic.
Alabi C; Vegas A; Anderson D
Curr Opin Pharmacol; 2012 Aug; 12(4):427-33. PubMed ID: 22726555
[TBL] [Abstract][Full Text] [Related]
35. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
[TBL] [Abstract][Full Text] [Related]
36. Small Interfering RNAs and their Delivery Systems: A Novel Powerful Tool for the Potential Treatment of HIV Infections.
Bolhassani A; Milani A
Curr Mol Pharmacol; 2020; 13(3):173-181. PubMed ID: 31760929
[TBL] [Abstract][Full Text] [Related]
37. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
39. Nanotechnology for in vivo targeted siRNA delivery.
Dahlman JE; Kauffman KJ; Langer R; Anderson DG
Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
[TBL] [Abstract][Full Text] [Related]
40. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
